Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Additional Paid-In Capital

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Additional Paid-In Capital

NAUT · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
728.25M
10.3%10.9%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
326.08M
26.0%N/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
729.94M
9.8%6.3%N/A
728.55M
4.1%4.8%48.7%
457.61M
10.3%69.1%N/A
498.66M
25.2%18.3%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
1.91B
2.2%4.7%8.2%
232.83M
12.0%9.9%N/A
191.29M
33.8%19.8%N/A
161.78M
23.0%27.1%16.0%
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58